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Abstract
Emerging studies implicate Tau as an essential mediator of
neuronal atrophy and cognitive impairment in Alzheimer’s disease
(AD), yet the factors that precipitate Tau dysfunction in AD are
poorly understood. Chronic environmental stress and elevated
glucocorticoids (GC), the major stress hormones, are associated
with increased risk of AD and have been shown to trigger intracel-
lular Tau accumulation and downstream Tau-dependent neuronal
dysfunction. However, the mechanisms through which stress and
GC disrupt Tau clearance and degradation in neurons remain
unclear. Here, we demonstrate that Tau undergoes degradation via
endolysosomal sorting in a pathway requiring the small GTPase
Rab35 and the endosomal sorting complex required for transport
(ESCRT) machinery. Furthermore, we find that GC impair Tau
degradation by decreasing Rab35 levels, and that AAV-mediated
expression of Rab35 in the hippocampus rescues GC-induced Tau
accumulation and related neurostructural deficits. These studies
indicate that the Rab35/ESCRT pathway is essential for Tau clear-
ance and part of the mechanism through which GC precipitate
brain pathology.
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Introduction
Intraneuronal accumulation of Tau protein represents a central
pathogenic process in Alzheimer’s disease (AD) and is hypothesized
to mediate the detrimental effects of amyloid-beta (Ab) on neuronal
function and cognitive performance (Roberson et al, 2007; Ittner
et al, 2010; Guo et al, 2017). Tau accumulation and hyperphospho-
rylation is linked to synaptic atrophy, neuronal dysfunction, and
cognitive deficits (Kimura et al, 2007; Yin et al, 2016), and triggers
these events by disrupting axonal trafficking (Vossel et al, 2010),
promoting GluN2B-related excitotoxicity (Ittner et al, 2010; Zempel
et al, 2010), and suppressing nuclear CREB-mediated synthesis of
synapse- and memory-related proteins (Yin et al, 2016), among other
effects. Furthermore, emerging studies support a crucial role for Tau
in diverse brain pathologies (for review, see Sotiropoulos et al, 2017)
including prolonged exposure to stressful conditions, a known risk
factor for AD and major depressive disorder (Vyas et al, 2016). In
particular, recent studies demonstrate that exposure to chronic envi-
ronmental stress or the major stress hormones, glucocorticoids (GC),
triggers the accumulation of Tau and its synaptic missorting, precipi-
tating dendritic atrophy and synaptic dysfunction in a Tau-dependent
manner (Pinheiro et al, 2015; Lopes et al, 2016a,b; Pallas-Bazarra
et al, 2016; Dioli et al, 2017). However, the cellular mechanisms
responsible for stress/GC-induced accumulation of Tau remain unclear.
A major cause of Tau accumulation is the dysfunction of its
degradative pathways (Khanna et al, 2016). Tau degradation has
been shown to occur through two distinct mechanisms, the ubiqui-
tin–proteasome system and the autophagy–lysosome pathway (Lee
et al, 2013; Zhang et al, 2017a). Indeed, proteasome and lysosome
inhibitors can delay Tau turnover and promote Tau-driven
neuropathology (Zhang et al, 2005; Hamano et al, 2008). However,
dysfunction of a third degradative pathway, the endolysosomal
system, is also linked to AD and other neurodegenerative conditions
that exhibit Tau accumulation, including Parkinson’s disease
(Rivero-Rios et al, 2015; Kett & Dauer, 2016; Small et al, 2017).
Nevertheless, the role of the endolysosomal pathway in the clear-
ance of Tau is almost completely unexplored.
Here, we report that the small GTPase Rab35 and the endosomal
sorting complex required for transport (ESCRT) machinery mediate
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the delivery of Tau to lysosomes via early endosomes and multi-
vesicular bodies (MVBs). We further demonstrate that this pathway
is negatively regulated by GC, which suppress Rab35 transcription,
thereby inhibiting Tau degradation and promoting its accumulation.
Finally, we show that in vitro and in vivo overexpression of Rab35
can rescue GC-induced Tau accumulation and neurostructural defi-
cits in hippocampal neurons. These findings demonstrate Rab35’s
critical role as a regulator of Tau clearance under physiological and
pathological conditions.
Results
The ESCRT pathway is necessary and sufficient for
Tau degradation
Despite its primarily axonal and microtubule-related distribution,
Tau is also found in the somatodendritic compartment and associ-
ated with lipid membranes (Pooler & Hanger, 2010; Georgieva et al,
2014). To determine whether Tau undergoes endosomal sorting, we
looked for Tau immunoreactivity in multivesicular bodies (MVBs),
late endosomal structures that deliver cargo to lysosomes. Immuno-
electron microscopy in rat hippocampal tissue revealed MVBs that
contain Tau immunogold labeling (Figs 1A and EV1A), indicating
that Tau is sorted into MVBs and can potentially undergo degrada-
tion via the endocytic pathway. MVB biogenesis is catalyzed by the
endosomal sorting complex required for transport (ESCRT) system, a
series of protein complexes that recruit ubiquitylated cargo destined
for degradation and facilitate the formation of intraluminal vesicles
(Raiborg & Stenmark, 2009). The initial component of the ESCRT-0
complex, Hrs, is essential for binding and recruitment of ubiquity-
lated cargo into MVBs (Raiborg & Stenmark, 2009; Frankel &
Audhya, 2017). To examine whether Hrs interacts with Tau, we
performed the proximity ligation assay (PLA; see Fig 1B) in N2a cells
overexpressing mCh-tagged Hrs (Figs 1C and EV1B). Here, we
detected fluorescent puncta, representing close (20–50 nm) proxim-
ity of Hrs and Tau, that were associated with Hrs-positive early endo-
somes (Fig 1C) and increased upon overexpression of GFP-tagged
wild-type Tau (GFP-wtTau; 0N4R isoform; Hoover et al, 2010;
Fig EV1C and D), demonstrating specificity of the PLA signal for the
Hrs/Tau interaction. This interaction was confirmed by coimmuno-
precipitation (IP) experiments in N2a cells overexpressing FLAG-Hrs
and either GFP or GFP-wtTau, wherein Hrs was specifically pulled
down by GFP-wtTau (Fig EV1E). Treatment with a deubiquitylating
enzyme (DUB) inhibitor to increase ubiquitylated Tau species further
increased the Hrs/Tau interaction as measured by both co-IP and
PLA (Fig EV1F–I), indicating that ubiquitylation promotes Tau’s
association with Hrs and subsequent entry into the ESCRT pathway.
Using super-resolution fluorescence microscopy, we also identified
Tau in both membranes and lumen of Hrs-, EEA1-, and Rab5-positive
early endosomes in N2a cells (Fig 1D and E). These findings demon-
strate the presence of Tau in endosomal compartments at both early
and late stages of the endolysosomal pathway.
Rab35 promotes Tau degradation through the ESCRT pathway
To assess the role of the ESCRT pathway in Tau clearance (Fig 2A),
we measured Tau degradation in primary hippocampal neurons
lentivirally transduced with an shRNA against TSG101, an essential
component of the ESCRT-I complex. Depletion of TSG101 is a
common mechanism for blocking degradation of ESCRT pathway
cargo (Edgar et al, 2015; Maminska et al, 2016), and our shTSG101
hairpin reliably reduces TSG101 levels by ~60% (Fig EV2A and B).
Using a previously described cycloheximide (CHX)-chase assay to
measure the fold change in Tau degradation (Sheehan et al, 2016),
we found that shTSG101 decreased this value by 30% (Fig 2B and
C), indicating its ability to inhibit Tau degradation. Conversely,
activation of the ESCRT pathway by TSG101 overexpression
increased Tau degradation by ~30% (Fig 2D and E). Together, these
findings indicate that the ESCRT pathway is both necessary and
sufficient for mediating Tau degradation.
In recent work, we demonstrated that ESCRT-0 protein Hrs is an
effector of the small GTPase Rab35 and is recruited by active Rab35
to catalyze downstream ESCRT recruitment and MVB formation
(Sheehan et al, 2016). Therefore, we investigated whether Rab35 is
also a key regulator of Tau degradation. Again using the CHX-chase
assay, we measured Tau degradation in neurons transduced with a
previously characterized shRNA to knockdown Rab35 (shRab35;
Fig EV2C and D; Sheehan et al, 2016). We found that shRab35
decreased Tau degradation by ~30% (Fig 2F and G), indicative of
Rab35’s role in this process. Moreover, overexpression/gain-of-func-
tion of mCherry-tagged Rab35 increased Tau degradation by nearly
50% compared to mCh control (Fig 2H and I), demonstrating that
Rab35 is a potent regulator of Tau turnover.
We further confirmed the effect of Rab35 on Tau with a flow
cytometry assay using N2a cells transfected with HA-Rab35 and
medium fluorescent timer (FT)-tagged wtTau (FT-Tau). The emis-
sion of medium FT changes from blue to red as it matures, with
half-maximal red fluorescence at 3.9 h (Fig 2J; Subach et al, 2009),
and this fluorophore has previously been used to monitor protein
degradation based on the intensities of red (“older”) vs. blue
(“younger”) fluorescent protein in cells (Fernandes et al, 2014). We
found that the ratio of red:blue (old:new) FT-Tau was significantly
lower in N2a cells co-expressing HA-Rab35 compared to HA vector
control (Fig 2K), indicating faster Tau degradation. Rab35 overex-
pression did not alter the red:blue ratio when FT alone was
expressed in N2a cells (Fig EV2E), confirming that Rab35 specifi-
cally stimulates Tau degradation. Given that Tau hyperphosphoryla-
tion is a key pathogenic event in AD and other tauopathies (Guo
et al, 2017), we also evaluated whether Rab35 could stimulate the
degradation of hyperphosphorylated Tau, using the phospho-
mimetic E14 Tau mutant, in which 14 serine and threonine residues
are replaced with glutamic acid (Hoover et al, 2010). The ratio of
red:blue FT-TauE14 was again significantly lower in HA-Rab35-
expressing N2a cells (Fig 2L), indicating Rab35’s ability to mediate
the degradation of phosphorylated Tau.
Since Tau is phosphorylated at multiple sites, we used anti-
bodies against several phospho-Tau epitopes related to pathogenic
Tau activity, including Ser396/404, Ser262, and Ser202, to deter-
mine which Tau species were sensitive to Rab35/ESCRT-mediated
degradation. Interestingly, we found that degradation of both
pSer396/404-Tau and pSer262-Tau (measured by CHX-chase
assay) was significantly slowed by knockdown of Rab35, while
pSer202-Tau was unaffected (Fig 3A and B). We saw similar
results with knockdown of TSG101 (Fig EV2F and G). To further
verify that Rab35 stimulates Tau degradation through the ESCRT
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Figure 1. Tau protein localizes to early endosomes and MVBs.
A Electron micrographs of immunogold-labeled Tau (arrows) in multivesicular bodies (yellow dashed lines) of rat hippocampus (scale bar: 250 nm).
B Schematic diagram of proximity ligation assay (PLA), wherein primary antibodies against Hrs or Tau are detected by secondary antibodies conjugated to DNA.
Ligation and amplification of DNA, resulting in green signal, only occurs when proteins are in close (20–50 nm) proximity.
C PLA signal (green) for Hrs/Tau interaction (arrows) on an mCh-Hrs-labeled endosome (red) in N2a cells; scale bar: 5 lm (see also Fig EV1).
D Super-resolution images of N2a cells transfected with constitutively active Rab5 (EGFP-Rab5-CA) and immunostained for Tau, revealing the presence of Tau in both
membranes and lumen of early endosomes (scale bar: 5 lm).
E Super-resolution images of N2a cells transfected with mCh-Hrs and immunostained for Tau and EEA1. Higher-magnification insets (A and B) show Hrs- and EEA1-
positive endosomes with juxtaposed Tau puncta present both in the membrane and lumen; scale bar: 5 lm.
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pathway, we assessed the effect of Rab35 on Hrs/Tau interaction
by PLA. Here, N2a cells were co-transfected with FLAG-Hrs and
mCherry or mCh-Rab35, and PLA performed with antibodies
against FLAG and either total or phospho-Tau epitopes. For total
Tau, as well as pSer396/404-Tau and pSer262-Tau, Rab35 expres-
sion significantly increased the number of fluorescent puncta per
cell (Fig 3C and D), representing increased interaction of these
Tau species with Hrs and thus their subsequent sorting into the
ESCRT pathway. In contrast, Rab35 had no effect on PLA puncta
number for pSer202-Tau (Fig 3C and D). Consistent with our
CHX-chase assay findings, these PLA data suggest that Rab35
promotes the degradation of Tau protein through the ESCRT path-
way, with some preference for Tau phosphorylated at pSer262
and pSer396/404, but not pSer202.
To verify that the Rab35/ESCRT pathway mediates Tau degrada-
tion through lysosomes, we next treated hippocampal neurons with
bafilomycin (to block acidification and trap lysosome contents) in
the presence of mCh-tagged TSG101 or Rab35 to stimulate Tau sort-
ing into this pathway (Fig 4A). We found that bafilomycin led to a
significant accumulation of Tau in lysosomes of neurons expressing
either TSG101 or Rab35 vs. mCh control, assessed by the fraction of
Tau colocalization with LAMP1 (Fig 4A and B). Furthermore,
through sucrose-based fractionation of primary neurons, we found
that Rab35 overexpression increased the fraction of Tau in endoso-
mal/lysosomal (Rab35- and LAMP1-enriched) fractions (Fig EV3),
providing further support for the stimulating role of Rab35 on Tau
sorting into the endolysosomal pathway. We also evaluated the
effects of Rab35 gain-of-function on Tau stability in different
neuronal compartments, using CHX treatment combined with
immunofluorescence microscopy in hippocampal neurons express-
ing mCh or mCh-Rab35, as previously described (Sheehan et al,
2016). Although both Rab35 and Tau are enriched in axons, Rab35
overexpression reduced Tau fluorescence in both axons and
neuronal somata by between 25 and 50%, demonstrating the ability
of Rab35 to stimulate Tau degradation in distinct neuronal compart-
ments (Fig 4C and D).
Glucocorticoids decrease Rab35 levels in vitro and in vivo
Clinical studies suggest that stressful life events and high GC
levels are risk factors for AD (Johansson et al, 2010; Machado
et al, 2014); and animal studies demonstrate that prolonged expo-
sure to environmental stress and/or elevated GC levels trigger
Tau accumulation (Lopes et al, 2016b,c; Vyas et al, 2016). Based
on our findings identifying the Rab35/ESCRT pathway as a criti-
cal regulator of Tau degradation, we next examined whether GC
treatment altered the levels of Rab35 or ESCRT pathway proteins.
Primary neurons were treated with GC and the levels of ESCRT
proteins (Hrs, TSG101, CHMP2b) and Rab35 measured. Interest-
ingly, we found that GC treatment selectively reduced Rab35
protein levels without altering the levels of other ESCRT proteins
(Fig 5A and B). GC are known to regulate gene transcription via
activation of the glucocorticoid receptor (GR), which binds gluco-
corticoid response elements (GRE) within the promoter regions of
genes (Vyas et al, 2016). We therefore used qPCR to measure
Rab35 mRNA levels in hippocampal neurons and N2a cells, and
found that GC treatment led to a significant reduction in Rab35
mRNA in both cell types (Fig 5C). Consistent with the concept
that GC regulate Rab35 transcription, we found that the Rab35
gene contains 14 non-redundant GREs (Table 1). We subsequently
measured the levels of Rab35 and other endocytic Rab GTPases
in the hippocampi of rats that received GC injections for 15 days
(Fig 5D). The hippocampus displays overt lesions in both stress-
and Tau-related pathologies and is one of the earliest brain
regions to show signs of neurodegeneration (Vyas et al, 2016). In
line with our in vitro findings, Rab35 levels were significantly
decreased in GC-injected animals, whereas none of the other Rab
GTPases analyzed had significantly altered levels as assessed by
immunoblot analysis (Fig 5E and F). We observed a similar
~25% decrease in immunofluorescence staining of Rab35 in the
dorsal CA1 area of hippocampus in GC-treated vs. control animals
(Figs 5G and H, and EV4A). Altogether, these in vitro and in vivo
results suggest that GC specifically decrease Rab35 transcription,
◀ Figure 2. Tau degradation occurs through the Rab35/ESCRT pathway.A Schematic diagram of the Rab35/ESCRT pathway, indicating the manipulation of targets (Rab35 and TSG101) used in our studies, and the final readout of Tau
degradation; green and red arrows represent overexpression and knockdown of the target proteins, respectively.
B, C Representative immunoblots (B) and quantification of Tau degradation (C) from 14 DIV primary neurons transduced with EGFP or shTSG101, treated for 24 h with
either DMSO (CON) or cycloheximide (CHX), and probed for Tau and tubulin. shTSG101-expressing neurons exhibit markedly decreased Tau degradation compared
to EGFP-expressing controls (n = 18–19 per condition, unpaired Student’s t-test, *P = 0.0108).
D, E Representative immunoblots (D) and quantification of Tau degradation (E) from 14 DIV neurons transduced with mCh or mCh-TSG101, treated for 24 h with either
DMSO (CON) or cycloheximide (CHX), and probed for Tau and tubulin. Overexpression of TSG101 increases Tau degradation (n = 17/condition, unpaired Student’s t-
test, *P = 0.0115).
F, G Representative immunoblots (F) and quantification of Tau degradation (G) from 14 DIV neurons transduced with mCh or shRab35, treated for 24 h with either
DMSO (CON) or cycloheximide (CHX), and probed for Tau and tubulin. shRab35-expressing neurons exhibit markedly decreased Tau degradation compared to mCh-
expressing controls (n = 23–26 per condition, unpaired Student’s t-test, ***P = 0.0008).
H, I Representative immunoblots (H) and quantification of Tau degradation (I) from 14 DIV neurons transduced with mCh or mCh-Rab35, treated for 24 h with either
DMSO (CON) or cycloheximide (CHX), and probed for Tau or tubulin. Rab35 overexpression increases Tau degradation (n = 18 per condition, unpaired Student’s t-
test, *P = 0.0126).
J Flow cytometry distribution of N2a cells co-transfected with either HA vector (black) or HA-Rab35 (green) and medium fluorescence timer-tagged wild-type Tau
(FT-Tau); blue fluorescence (y axis) indicates “younger” Tau protein, while red fluorescence (x axis) indicates “older” Tau.
K The ratio of cells expressing red to blue (older:younger) FT-Tau is reduced in cells overexpressing Rab35, indicating faster Tau turnover (n = 9/condition, unpaired
Student’s t-test, ****P < 0.0001).
L The ratio of cells expressing red to blue (older:younger) FT-tagged phospho-mimetic E14 Tau (FT-TauE14) is also reduced in cells overexpressing Rab35, indicating
that Rab35 also triggers degradation of phosphorylated Tau (n = 10/condition, unpaired Student’s t-test, *P = 0.0032).
Data information: All numeric data represent mean  SEM.
Source data are available online for this figure.
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Figure 3. Phospho-dependent selectivity of Tau sorting into the Rab35/ESCRT pathway.
A, B Representative immunoblots (A) and quantification of Tau degradation (B) from 14 DIV primary neurons transduced with mCh or shRab35, treated for 24 h with
either DMSO (CON) or cycloheximide (CHX), and probed for pSer396/404-Tau (PHF1), pSer262-Tau, or pSer202-Tau (CP13) and tubulin. shRab35-expressing neurons
exhibit markedly decreased pSer262- and p396/404-Tau degradation compared to mCh-expressing controls, while pSer202-Tau degradation is unaffected (n = 4
per condition for pSer396/404-Tau and pSer202-Tau, n = 3 for pSer262-Tau, unpaired Student’s t-test, **P = 0.0027, *P = 0.0120).
C Images of PLA signal (green) for Hrs/Tau interaction in N2a cells co-transfected with FLAG-Hrs and either mCh or mCh-Rab35 (red), and probed with antibodies
against FLAG and total (DA9) or phospho-Tau species (pSer396/404-Tau, pSer262-Tau, or pSer202-Tau); scale bar: 5 lm.
D Rab35 overexpression significantly increases PLA puncta for total, pSer396/404-Tau, pSer262-Tau but not pSer202-Tau (n = 121–132 cells for total Tau, 178–195 cells
for pSer396/404-Tau, 71–98 cells for pSer262-Tau, 25–29 cells for pSer202-Tau; Mann–Whitney U-test, ****P < 0.0001).
Data information: All numeric data represent mean  SEM.
Source data are available online for this figure.
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leading to reduced Rab35 mRNA and protein levels in hippocam-
pal neurons.
Rab35 gain-of-function rescues GC-induced Tau accumulation
and neurostructural deficits
Based on our findings that Rab35 mediates Tau turnover, and that
exposure to high GC levels downregulates Rab35, we hypothesized
that Rab35 overexpression could attenuate GC-induced Tau accumu-
lation and related neuronal atrophy (Green et al, 2006; Sotiropoulos
et al, 2011; Pinheiro et al, 2015). To test this hypothesis, we
performed the CHX-chase assay in hippocampal neurons transduced
with either mCh or mCh-Rab35, and treated with GC or vehicle
control. As shown in Fig 6, GC treatment reduced Tau degradation
in mCherry-expressing neurons, but this effect was completely
blocked by Rab35 overexpression (Fig 6A and B). Similar results
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Figure 4. Rab35/ESCRT pathway promotes Tau degradation via lysosomes.
A, B Representative images and quantification of 14 DIV neurons transduced with mCh, mCh-TSG101, or mCh-Rab35, treated for 5 h with either DMSO (CON) or
bafilomycin (Baf) to block lysosomal degradation, and immunostained for Tau and LAMP1. Overexpression of Rab35 or TSG101 increases Tau accumulation in
lysosomes of Baf-treated neurons, indicating that Rab35/ESCRT pathway activation stimulates sorting of Tau into lysosomes (scale bar: 5 lm) (n = 25–27
cells/condition; for TSG101, two-way ANOVA, Baf × TSG101 interaction F1,99 = 4,075 P = 0.04, overall Baf effect F1,99 = 10.30 P = 0.0018, Sidak post hoc analysis
***P = 0.0007; for Rab35, two-way ANOVA, Baf × Ra35 interaction F1,101 = 5.36 P = 0.02, overall Baf effect F1,101 = 12.01 P = 0.0008, Sidak post hoc analysis
***P = 0.0001). All numeric data represent mean  SEM.
C Images of 14 DIV neurons transduced with mCh or mCh-Rab35, treated for 24 h with either DMSO (CON) or cycloheximide (CHX) and immunostained for Tau; scale
bar: 10 lm.
D Tau fluorescence intensity is markedly reduced in both soma and axons of CHX-treated neurons overexpressing Rab35 compared to mCh, indicating faster Tau
degradation (n = 24/condition; for axons, n = 25–26/condition); for soma, two-way ANOVA, overall CHX effect F1,92 = 19.27 P < 0.0001, Sidak post hoc analysis
***P = 0.002; for axon, two-way ANOVA, CHX × Rab35 interaction F1,97 = 13.27 P = 0.0004, overall CHX effect F1,97 = 14.34, P = 0.0003, Sidak post hoc analysis
****P < 0.0001).
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were seen in N2a cells, where Rab35 overexpression prevented the
GC-driven increase in total Tau levels (Fig EV4B and C) and in ubi-
quitylated Tau species (Fig EV4D–F). Since ubiquitylation is the
major signal for cargo sorting into the ESCRT pathway, these find-
ings provide further evidence that Rab35 stimulates the endolysoso-
mal sorting of ubiquitylated Tau.
Previous studies showed that exposure to stress or high GC levels
induced Tau accumulation, dendritic atrophy, and synapse loss in
animals (Pinheiro et al, 2015; Lopes et al, 2016b), and that these
hippocampal deficits were Tau-dependent (Lopes et al, 2016a,b). To
test whether Rab35 could protect against these GC-induced effects,
we injected middle-aged rats with adeno-associated virus (AAV) to
express EGFP or EGFP-Rab35 in excitatory neurons of the
hippocampus under control of the CaMKIIa promoter (Fig 6C).
Animals were subsequently treated with GC or vehicle control. Both
EGFP- and EGFP-Rab35-injected animals displayed similar body
mass loss following GC administration, demonstrating a similar
response to high GC levels in the presence or absence of overex-
pressed Rab35 (Fig EV5A–C). However, in contrast to EGFP animals
that exhibited significant GC-induced Tau accumulation in
hippocampal synaptosomes, animals expressing EGFP-Rab35 did
not show any such accumulation (Fig 6D and E). Furthermore,
using Golgi-based 3D neuronal reconstruction of CA1 pyramidal
neurons in hippocampus, we found that GC significantly decreased
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Figure 5. Glucocorticoids decrease Rab35 levels in vitro and in vivo.
A, B Representative immunoblots (A) and quantification of Hrs, TSG101, CHMP2b, and Rab35 protein levels (B) from 14 DIV neurons treated with either DMSO (CON) or
glucocorticoids (GC). GC treatment selectively decreases Rab35 protein levels without affecting levels of Hrs, TSG101, or CHMP2b (n = 9–10/condition, unpaired
Student’s t-test, *P = 0.0221).
C Rab35 mRNA levels are decreased by GC in 14 DIV hippocampal neurons and N2a cells (for neurons, n = 9/condition, unpaired Student’s t-test, **P = 0.0036; for
N2a cells, n = 6/condition, unpaired Student’s t-test, *P = 0.0138).
D Schematic diagram of GC and vehicle control (CON) treatment in rats for 15 days.
E, F Representative immunoblots (E) and quantification of levels of different Rab proteins (F) in hippocampus of GC-treated and CON animals. Protein levels of Rab35,
but not other Rabs, are decreased in GC-treated animals compared to CON ones (n = 5 animals/condition, unpaired Student’s t-test, *P = 0.0257).
G, H Immunofluorescence staining of Rab35 (green) and DAPI (blue) (G) showing that Rab35 fluorescence intensity is reduced in hippocampal area (CA1) of GC-treated
animals (H) (n = 15 slices/condition; unpaired Student’s t-test, ***P = 0.0003).
Data information: All numeric data represent mean  SEM.
Source data are available online for this figure.
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the length of apical dendrites in the EGFP control group, but not in
animals expressing EGFP-Rab35 (Fig 6F and G). Notably, EGFP-
Rab35 expression alone did not alter apical dendritic length
(Fig 6G), and no difference in basal dendrite length was found
between the groups (Fig EV5D), consistent with previous work
showing selective vulnerability of apical dendrites to GC (Lopes
et al, 2016b). We also found that GC treatment led to a significant
loss of mature spines and concomitant increase in immature spines
in EGFP-expressing animals, but no change in mature or immature
spine density in EGFP-Rab35 animals (Figs 6H and EV5E). GC-
induced neuronal atrophy was further confirmed by Sholl analysis,
which measures the number of dendritic intersections as a function
of their distance from the soma. As shown in Fig 6I and J, GC
reduced the number of distal dendritic intersections in neurons
expressing EGFP but not EGFP-Rab35. Altogether, these in vivo find-
ings indicate that Rab35 overexpression prevents GC-driven
neurostructural deficits, implicating Rab35 as an essential regulator
of GC-induced neuronal dysfunction.
Discussion
Impairment of Tau proteostasis is linked to neuronal and synaptic
dysfunction in AD animal models and patients (Roberson et al,
2007; Ittner et al, 2010; Guo et al, 2017). Given that Tau accumula-
tion appears to drive neurodegenerative processes in AD and other
neurological diseases (see also Introduction), there is growing inter-
est in understanding the mechanisms that mediate Tau clearance,
and their selectivity for different forms of Tau. Previous studies
have shown that Tau degradation can occur through the ubiquitin–
proteasome system (UPS), but that macroautophagy plays an impor-
tant role in the catabolism of aggregated/insoluble Tau, which is
not accessible to the UPS (for review, see Chesser et al, 2013).
Recent work indicates that chaperone-mediated autophagy and
endosomal microautophagy also contribute differentially to the
degradation of wild-type vs. pathogenic mutants forms of Tau
(Caballero et al, 2017), suggesting that Tau turnover is a complex
process regulated by multiple factors and involving distinct degrada-
tive pathways.
The current study utilizes in vitro and in vivo approaches to
demonstrate a critical role for the endocytic pathway, and in
particular Rab35 and the ESCRT machinery, in the turnover of
total Tau and specific phospho-Tau species (see Fig 7). The ESCRT
system mediates the degradation of membrane-associated proteins
such as epidermal growth factor receptor (Raiborg & Stenmark,
2009), but it has also been implicated in the degradation of cytoso-
lic proteins GAPDH and aldolase (Sahu et al, 2011). These find-
ings are of particular relevance for Tau, which has both cytosolic
and membrane-associated pools (Pooler & Hanger, 2010; Geor-
gieva et al, 2014), and has been shown to localize to different
neuronal subcompartments based on its phosphorylation state
(Hoover et al, 2010; Pinheiro et al, 2015). The current study
reveals that Tau appears in Hrs-, EEA1-, and Rab5-positive early
endosomes (on the membrane and in the lumen), intraluminal
vesicles of MVBs, and LAMP1-positive vesicles and membrane
fractions, demonstrating its trafficking through the entire endolyso-
somal pathway. Moreover, we find that Tau interacts with the
initial ESCRT protein Hrs, and that this interaction is strengthened
by deubiquitylating enzyme inhibitors, indicating its dependence
on Tau ubiquitylation. We also observe that the small GTPase
Rab35 is a positive regulator of Tau sorting into the ESCRT path-
way. Not only does overexpression of Rab35 stimulate Tau’s inter-
action with Hrs and subsequent lysosomal degradation, but Rab35
knockdown significantly slows Tau degradation. Interestingly,
while Rab35 stimulates the turnover of phospho-mimetic E14 Tau,
not all phosphorylated Tau species are equally susceptible to
degradation in the Rab35/ESCRT pathway. In particular, we find
that pSer396/404 and pSer262, but not pSer202, phospho-Tau
species undergo Rab35-mediated degradation, indicative of prefer-
ential sorting of specific phospho-Tau proteins into the Rab35/
ESCRT pathway. Such differences might reflect changes in ubiqui-
tylation and/or endosomal membrane association of the various
phospho-Tau species. Additional work is needed to clarify the rela-
tionship between Tau posttranslational modifications (e.g., phos-
phorylation and ubiquitylation) and the sorting and clearance of
cytosolic vs. membrane-associated pools of Tau, as well as the
impact of stress/GC on these processes.
We recently showed that Rab35 and ESCRT proteins (e.g., Hrs,
CHMP2b) localize to axons and presynaptic boutons, similar to Tau,
and that Rab35 stimulates the degradation of synaptic vesicle
proteins by mediating the recruitment of Hrs to SV pools in response
to neuronal activity (Sheehan et al, 2016). In the current study, we
show that Tau interacts with Hrs-positive early endosomes in a
Rab35-dependent manner, and that Rab35 stimulates the degrada-
tion of both axonal and somatodendritic pools of Tau. Although Tau
localizes primarily to axons, many studies (including our own) have
shown that it also localizes to the somatodendritic compartment
and to dendritic spines under both healthy and pathological condi-
tions, suggesting a synaptic function for Tau (Ittner et al, 2010;
Mondragon-Rodriguez et al, 2012; Frandemiche et al, 2014;
Pinheiro et al, 2015; Lopes et al, 2016c). Moreover, recent work
demonstrates more complex intraneuronal trafficking of Tau than
Table 1. Chromosomal position of GR binding sites for Rab35 gene.
Position Chromosome Start End
1 chr5 115630873 115630972
2 chr5 115631594 115631675
3 chr5 115631971 115632003
4 chr5 115632442 115632541
5 chr5 115632583 115632682
6 chr5 115633507 115633606
7 chr5 115633735 115633834
8 chr5 115635642 115635723
9 chr5 115635734 115635827
10 chr5 115637535 115637616
11 chr5 115640541 115640640
12 chr5 115645909 115646008
13 chr5 115646118 115646217
14 chr5 115647366 115647465
Our analysis identified 14 distinct glucocorticoid response elements
associated with the Rab35 gene, indicating the relevance of glucocorticoids
for regulating Rab35 transcription.
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Figure 6. AAV-mediated Rab35 expression rescues glucocorticoid-induced Tau accumulation and associated neuronal atrophy in rat hippocampus.
A, B Representative immunoblots (A) and quantification of Tau degradation (B) in 14 DIV neurons expressing mCh-Rab35 or mCh, treated for 24 h with cycloheximide
(CHX) or DMSO (CON) under GC conditions. GC significantly decreases Tau degradation, whereas Rab35 overexpression blocks this effect (n = 12–14/condition; one-
way ANOVA, Dunnet post hoc analysis, *PmCh vs. mCh GC = 0.0319, *PmCh vs. Rab35 GC = 0.047).
C Injection of AAV to express EGFP or EGFP-Rab35, driven by the CaMKIIa promoter, in rat hippocampus prior to GC or vehicle (CON) treatment.
D, E Representative immunoblots (D) and quantification of Tau levels (E) in hippocampal synaptosomes reveal that GC increases total Tau levels in animals expressing
EGFP, but not Rab35 (n = 5–6 animals/group, two replicates, two-way ANOVA, GC × Rab35 interaction F1,39 = 10.51 P = 0.002; Sidak post hoc analysis *P = 0.0168).
F Golgi-based 3D neuronal reconstruction of hippocampal pyramidal neurons (CA1 area).
G GC treatment reduces the length of apical dendrites in animals expressing EGFP, but not EGFP-Rab35 (n = 6–7 animals/group; 6–8 neurons/animal, 2-way ANOVA,
GC × Rab35 interaction F1,155 = 3.969 P = 0.0481, overall GC effect F1,155 = 8.998 P = 0.0031, Sidak post hoc analysis **P = 0.0021).
H GC treatment reduces mature spine density in animals expressing EGFP, but not EGFP-Rab35 (two-way ANOVA, GC × Rab35 interaction F1,499 = 12.33 P = 0.0005,
overall GC effect F1,499 = 4.373 P = 0.0370, Sidak post hoc analysis ***P = 0.0003; n = 6–7 animals/group; 6–8 neurons per animal).
I, J Sholl analysis of apical dendrites in rat hippocampus shows reduced dendritic intersections after GC treatment in EGFP-expressing animals; however, this effect is
not seen in EGFP-Rab35-expressing animals (three-way ANOVA, GC × Rab35 interaction F1,4,212 = 14,926 P < 0.0001, simple effect analysis, Sidak test for multiple
comparisons *P120 = 0.012, **P140 = 0.001, **P220 = 0.002, ***P240 < 0.001, ***P260 < 0.001, **P280 = 0.001, **P300 = 0.001, *P320 = 0.021, *P340 = 0.047, n = 6–7
animals/group, 6–8 neurons per animal).
Data information: All numeric data represent mean  SEM.
Source data are available online for this figure.
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previously appreciated, including activity-dependent translocation
of Tau to excitatory synapses (Frandemiche et al, 2014) and AMPA/
NMDA receptor-dependent Tau hyperphosphorylation and dendritic
Tau mRNA translation (Kobayashi et al, 2017). Interestingly, our
current findings demonstrate the selective sorting of particular phos-
pho-Tau species into the Rab35/ESCRT pathway, which together
with other studies (Pooler & Hanger, 2010; Mondragon-Rodriguez
et al, 2012; Frandemiche et al, 2014; Pinheiro et al, 2015) provides
novel mechanistic insights into how epitope-specific Tau phospho-
rylation regulates its trafficking, subcellular localization, and degra-
dation. Our future studies will focus on understanding the role of
the Rab35/ESCRT pathway on Tau degradation in different neuronal
compartments under pathological conditions, including AD and
other tauopathies, wherein Tau is hyperphosphorylated at multiple
epitopes (Ittner et al, 2010; Zempel et al, 2010).
Recent evidence suggests that dysfunction of the ESCRT
machinery itself is associated with profound cytopathology, as
brain-specific deletion of ESCRT components in mice leads to the
accumulation of ubiquitylated proteins, impaired endosomal traf-
ficking, and cell death (Watson et al, 2015; Oshima et al, 2016).
Further, a truncating mutation in ESCRT-III protein CHMP2b
causes familial frontotemporal dementia and amyotrophic lateral
sclerosis, and at the cellular level induces endolysosomal pathway
dysfunction and the accumulation of ubiquitylated proteins
(Clayton et al, 2015; Zhang et al, 2017b). Together with our
findings, the above studies support the importance of the
endolysosomal pathway, and specifically the ESCRT machinery, in
clearance of ubiquitylated proteins such as Tau. Indeed, abnormal-
ities of the endolysosomal pathway, including endosomal enlarge-
ment and high levels of lysosomal hydrolases, are reported as the
earliest intracellular features of AD (Nixon & Yang, 2011). Intrigu-
ingly, these same features are present in Niemann-Pick disease
type C (NPC), an inherited lysosomal storage disorder also charac-
terized by Tau pathology (Suzuki et al, 1995). These shared
pathological features of AD and NPC indicate a strong connection
between endolysosomal dysfunction and Tau accumulation,
supporting the importance of this degradative pathway for Tau
proteostasis and pathological accumulation.
Multiple cellular pathways are altered by chronic stress,
increasing the vulnerability of affected individuals to psychiatric
and neurodegenerative diseases such as depression and AD
(Sotiropoulos et al, 2008b; Ross et al, 2017). For example,
prolonged exposure to stress or high levels of GC trigger Tau accu-
mulation and hyperphosphorylation accompanied by synaptic
missorting of Tau and neuronal atrophy (Green et al, 2006;
Sotiropoulos et al, 2011; Pinheiro et al, 2015; Lopes et al, 2016c).
Importantly, Tau is essential for this stress/GC-driven damage, as
Tau ablation was found to be neuroprotective (Lopes et al, 2016c;
Pallas-Bazarra et al, 2016; Dioli et al, 2017). While previous
in vitro studies showed that GC reduce Tau turnover (Sotiropoulos
et al, 2008a), the underlying molecular mechanisms were unclear.
The current study demonstrates that GC impair Tau degradation
by downregulating Rab35, thereby suppressing Tau sorting into
the ESCRT pathway and leading to the accumulation of ubiquity-
lated Tau (Fig 7). These results support the concept that ubiquity-
lation, the major signal for cargo sorting into the ESCRT pathway,
represents the first line of cellular defense against Tau accumula-
tion and related neuronal malfunction (Chesser et al, 2013;
Kontaxi et al, 2017). Importantly, we find that Rab35 overexpres-
sion blocks Tau accumulation and neuronal atrophy induced by
high GC levels. Future studies will clarify the potential interplay
between endolysosomal machinery and other degradative path-
ways such as autophagy under stressful/high GC conditions. Our
current findings identify the Rab35/ESCRT pathway as a critical
regulator of Tau proteostasis, supporting its involvement in the
intraneuronal events through which the primary stress hormones,
GC, impair neuronal morphology, and plasticity in the hippocam-
pus (Sousa & Almeida, 2012). Based on the emerging significance
of endosomal trafficking defects in AD brain pathology (Small
et al, 2017), Rab35 and the endolysosomal pathway deserve
further investigation for their therapeutic relevance against Tau-
dependent neuronal malfunction and pathology.
Figure 7. High glucocorticoid levels suppress Rab/ESCRT-dependent Tau degradation, leading to Tau accumulation.
Working model of Tau degradation through the Rab35/ESCRT pathway, and its inhibition by glucocorticoids (GC). Rab35 mediates Tau clearance via the endolysosomal
pathway by recruiting initial ESCRT component Hrs, which recognizes and sorts ubiquitylated Tau into early endosomes for packaging into MVBs. GC suppress transcription
of Rab35, which in turn decreases Tau sorting into MVBs and its subsequent degradation by lysosomes, leading to Tau accumulation and related neuronal atrophy.
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Materials and Methods
Primary neurons and cell lines
Primary neuronal cultures were prepared from E18 Sprague Dawley
rat embryos and maintained for 14 DIV before use, as described
previously (Sheehan et al, 2016). Neuro2a (N2a) neuroblastoma
cells (ATCC CCL-131) and HEK293T cells (Sigma) were grown in
DMEM-GlutaMAX (Invitrogen) with 10% FBS (Atlanta Biological)
and Anti-Anti (ThermoFisher) and kept at 37°C in 5% CO2. During
dexamethasone treatment in N2a cells, FBS content in the growth
media was reduced to 3%.
Pharmacological treatments
Pharmacological agents were used in the following concentrations
and time courses: cycloheximide (Calbiochem, 0.2 lg/ll, 24 h or
0.1 lg/ll, 16 h), bicuculline (Sigma, 40 lM, 24 h), 4-aminopyridine
(Tocris Bioscience, 50 lM, 24 h), bafilomycin A1 (Millipore,
0.1 lM, 5 h), dexamethasone (Ratiopharm, 10 lM, 48 h), dexam-
ethasone (InvivoGen, 20 lM, 72 h), epoxomicin (Sigma, 0.1 lM)
PR-619 (LifeSensors, 50 lM).
Lentivirus production, transduction, and DNA transfection
DNA constructs were described previously (Sheehan et al, 2016),
with the exception of pRK5-EGFP-Tau (Addgene plasmid
#46904), and pAAV-CAMKIIa-EGFP-Rab35, which was created by
subcloning EGFP-Rab35 into the pAAV-CAMKIIa-EGFP vector
(Addgene plasmid #50469). Both pAAV-CAMKIIa-EGFP-Rab35
and pAAV-CAMKIIa-EGFP were then packaged into AAV8 sero-
type by the UNC Gene Therapy Center Vector Core (UNC Chapel
Hill). Lentivirus was produced as previously described (Sheehan
et al, 2016). Neurons were transduced with 50–150 ll of lentivi-
ral supernatant per well (12-well plates) or 10–40 ll per cover-
slip (24-well plates) either at 3 DIV for shRNA transduction or
10 DIV in gain-of-function experiments. Respective controls were
transduced on the same day for all experimental conditions.
Neurons were collected for immunoblotting or immunocytochem-
istry at 14 DIV.
Immunofluorescence microscopy
Immunofluorescence staining in neurons and N2a cells was
performed as previously described (Sheehan et al, 2016). Briefly,
cells were fixed with Lorene’s Fix (60 mM PIPES, 25 mM
HEPES, 10 mM EGTA, 2 mM MgCl2, 0.12 M sucrose, 4%
formaldehyde) for 15 min, and primary and secondary antibody
incubations were performed in blocking buffer (2% glycine, 2%
BSA, 0.2% gelatin, 50 mM NH4Cl in 1× PBS) overnight at 4°C
or for 1 h at room temperature, respectively. For staining of
brain slices, coronal vibratome sections (40 lm) of paraformalde-
hyde-fixed brains were placed in heated citrate buffer for
15 min. Sections were then permeabilized using 0.5% Triton X-
100 for 30 min, followed by 5 min blocking with Ultravision
Protein Block (Thermoscientific). Primary and secondary antibod-
ies were diluted in 0.5% Triton/0.2% BSA/0.5% FBS in 1× PBS,
and incubation was performed overnight at 4°C or for 3 h at
room temperature, respectively. Images were acquired using a
Zeiss LSM 800 confocal microscope equipped with Airyscan
module, using either a 63× objective (Plan-Apochromat, NA 1.4),
for neurons or N2a cell imaging, or a 40× objective (Neofluar,
NA 1.4) for imaging of rat brain sections. Primary antibodies are
listed in Table EV1.
Proximity ligation assay
Proximity ligation assay (PLA) was performed in N2a cells accord-
ing to manufacturer’s instructions (Duolink, Sigma). Until the PLA
probe incubation step, all manipulations were performed as
detailed above for the immunocytochemistry procedure. PLA
probes were diluted in blocking solution. The primary antibody
pairs used were anti-FLAG (Rabbit; Abcam) and DA9 (anti-Total
Tau, Mouse, gift from Peter Davies), anti-FLAG (Rabbit, Abcam)
and PHF1 (Mouse), anti-FLAG (Rabbit, Abcam) and CP13
(Mouse), anti-FLAG (Mouse, Sigma) and pSer262 Tau (Rabbit,
ThermoFisher Scientific), anti-mCherry (Rabbit, Biovision), and
DA9 (Mouse, Peter Davies). Additionally, a blocking FLAG peptide
(Sigma), used at a 100 lg/ml concentration, was included to eval-
uate the specificity of the technique. All protocol steps were
performed at 37°C in a humidity chamber, except for the washing
steps. Coverslips were then mounted using Duolink In situ Mount-
ing Media with DAPI.
Tau immunogold staining and electron microscopy
For electron microscope analysis, rat hippocampi were fixed at 4°C
with 4% PFA, then transferred to 4% PFA/0.8% glutaraldehyde in
0.1 M of phosphate buffer (PB) for 1 h and afterward, to 0.1 M PB.
Vibratome-cut axial sections of the dorsal hippocampus (300 lm
thick) were collected, and CA1 hippocampal area was surgically
removed. Tissue was then carefully oriented and embedded in Epon
resin, and ultrathin sections (500 A˚), encompassing the superficial-
to-deep axis, were cut onto nickel grids. For Tau immunogold
staining, sections were treated with heated citrate buffer (Thermo
Scientific) for 30 min and then by 5% BSA. Grids were incubated
overnight with Tau5 primary antibody diluted in 1% BSA in PB,
followed by secondary gold antibody (Abcam). Grids were imaged
on a JEOL JEM-1400 transmission electron microscope equipped
with a Orius Sc1000 digital camera.
Image analysis
Images were analyzed and processed using the Fiji software. PLA
puncta were counted using the Multi-point tool, and cell area was
measured with Polygon selection tool. Fluorescence intensity was
measured after performing a Z-projection using the SUM function.
For cell bodies, the corrected total cell fluorescence was calcu-
lated, by subtracting the average fluorescence of the background
of the whole area to the Integrated fluorescence density. For
Axons, a mask was created in the mCherry channel, representing
the experimental condition, using the same threshold value, and
the average fluorescence intensity of the axon was then measure
in the other channel. Average fluorescence intensity per slice was
measured in images acquired from immunofluorescence stained
brain slices.
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Coimmunoprecipitation
For coimmunoprecipitation, N2a cells were transfected with Lipofec-
tamine 3000 according to the manufacturer’s protocol (Life Tech-
nologies). Cell lysates were collected 48 h after transfection, after 3×
washes with cold PBS, in Co-IP lysis buffer (0.1% NP-40, 1 mM
EDTA in 1× PBS) with protease inhibitor (Roche) and phosphatase
inhibitor cocktails II and III (Sigma) and clarified by centrifugation
at high speed (10 min, 20,000 g). Protein concentration was deter-
mined using the BCA protein assay kit (ThermoFisher Scientific),
and the same amount of protein was used for each condition.
Lysates were pre-cleared using magnetic agarose beads (Chromotek)
for 1 h at 4°C. For GFP pull down, lysates were incubated with GFP-
Trap Magnetic agarose beads (Chromotek) for 3 h at 4°C. Beads
were washed three times with co-IP lysis buffer and then eluted
using 2× sample buffer (Bio-Rad) and subject to SDS–PAGE
immunoblotting as described below.
Western blotting
For Western blotting experiments, neurons were collected using 2×
SDS sample buffer (Bio-Rad). N2a cells were first collected in Lysis
Buffer as described previously. Samples were subject to SDS–PAGE,
transferred to nitrocellulose membranes using wet or semi-dry appa-
rati (Mini Trans-Blot Cell or Trans-Blot Turbo Blotting System,
respectively, Bio-Rad), and probed with primary antibody
(Table EV1) in 5% BSA/PBS + 0.1% Tween-20, followed by
DyLight 680 or 800 anti-rabbit, anti-mouse (Thermo Scientific) or by
HRP-conjugated secondaries (Bio-Rad). Membranes were imaged
using an Odyssey Infrared Imager (model 9120, LI-COR Bios-
ciences), and protein intensity was measured using the Image Studio
Lite software (LI-COR Biosciences).
Cycloheximide-chase fold change calculation
In cycloheximide-chase experiments, the amount of protein remain-
ing after 24 h of cycloheximide treatment was calculated as a frac-
tion of the amount of protein in the DMSO-treated condition, as
previously described (Sheehan et al, 2016). Both levels were previ-
ously normalized to the tubulin loading control. The fractional
degradative amount of each condition was then normalized to the
experimental control by dividing the perturbation condition by the
control condition.
Subcellular fractionation with sucrose step gradient
For each gradient, two T75 culture flaks of primary cortical neurons
(7,500,000 cells each) were used. All procedures were carried out at
4°C post-collection and performed as described previously (de
Araujo et al, 2008), with slight modifications. Briefly, neurons were
detached from the flask with TrypLE Express (Life Technologies)
and washed once with ice-cold Neurobasal and twice with ice-cold
PBS. Neurons were then subject to hypotonic shock and allowed to
swell on ice for 15 min. After cell resuspension in isotonic condi-
tions, neurons were gently lysed with 3× freeze–thaw cycles. The
lysates were centrifuged (2,000 × g, 10 min, 4°C), and the postnu-
clear supernatant (PNS) was brought to 40.6% sucrose and loaded
in the bottom of a centrifugation tube, overlaid with 35% sucrose,
followed by 25% sucrose and then 8% sucrose solution (in ddH2O,
3 mM imidazole, pH 7.4 with protease and phosphatase inhibitors).
After centrifugation in a Beckman centrifuge (3 h, 210,000 × g,
4°C), thirteen 100 ll fractions were collected and equal volumes
were used for Western blotting, as previously described. Relative
protein distribution was calculated after determining the optical
density of each fraction and further normalizing against the sum of
all fractions. Fractions were divided into different groups according
to their respective sucrose gradient.
Real-time RT–PCR
RNA was extracted from either cortical neurons or N2a cells using
TRIzol (Thermo Fischer) and purified using the Direct-zol RNA
MiniPrep Plus kit (Zymo Research). RT–PCR was performed in a
StepOnePlus RealTime PCR instrument, with iTaqTM Universal
Probes One-Step Kit (Bio-Rad), using pre-designed TaqMan probes.
Amplification conditions were the following: initial denaturing at
95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s and
extension at 60°C for 1 min. Rab35 levels were normalized to either
b-actin (actb) or TATA-binding protein (tbp). Results presented are
normalized to b-actin.
Flow cytometry
N2a cells were detached using TrypLE Express (Life Technologies),
for 5 min at 37°C. After washing, cells were resuspended in ice-cold
Flow Buffer (0.2% FBS, 0.5 mM EDTA in PBS) and strained through
a 35-lm nylon mesh to promote single cell suspensions and kept on
ice. Cells were analyzed in a BD Fortessa (BD Biosciences).
Unstained cells were used as a control for background fluorescence.
Flow Cytometry data were analyzed using FCS Express 6 (DeNovo
Software).
Ubiquitylation assay
N2a cells were transfected with vectors encoding GFP-Tau and HA-
Ubiquitin with either mCherry or mCh-Rab35. After 48 h, cells were
treated with DMSO vehicle or Dexamethasone, and incubated for
another 43 h. Cells were then incubated with chloroquine,
leupeptin, and epoxomicin for 5 h. Cell lysates were collected,
washed 3× with cold PBS in Lysis buffer (50 mm Tris-Base, 150 mm
NaCl, 1% Triton X-100, 0.5% deoxycholic acid) with protease inhi-
bitor (Roche) and phosphatase inhibitor cocktails II and III (Sigma),
and clarified by centrifugation at high speed (10 min, 20,000 g).
Subsequent steps were performed as described in the coimmuno-
precipitation section.
Animals and AAV injection
Eight- to 10-month-old male Wistar rats (Charles River Laboratories,
Spain; N = 5 per group) were paired under standard laboratory
conditions (8:00 A.M. to 8:00 P.M.; 22°C) with ad libitum access to
food and drink. Animals received daily subcutaneous injections of
the synthetic glucocorticoid, dexamethasone (GC) (300 lg/kg;
Sigma D1756; dissolved in sesame oil containing 0.01% ethanol;
Sigma S3547) for 14 sequential days, while the other half received
daily injections of the vehicle solution (sesame oil with 0.01%
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ethanol). All experimental procedures were approved by the local
ethical committee of University of Minho and national authority for
animal experimentation; all experiments were in accordance with
the guidelines for the care and handling of laboratory animals, as
described in the Directive 2010/63/EU. For AAV injection experi-
ment (N = 6–8 per group), animals were anaesthetized with 75 mg/
kg ketamine (Imalgene, Merial) plus 0.5 mg/kg medetomidine (Dor-
bene, Cymedica). Virus was bilaterally injected into the dorsal and
ventral hippocampus (coordinates from bregma, according to Paxi-
nos and Watson 50: 3.0 mm anteroposterior (AP), 1.6 mm
mediolateral (ML), and 3.3 mm dorsoventral (DV) and 6.2 mm
AP, 4.5 mm ML, and 6.0 mm DV, respectively). A total of 2 ll
was injected at a rate of 200 nl/min, and the needle was kept in
place for 7 min before retraction. Rats were removed from the
stereotaxic frame, sutured, and allowed to recover for 3 weeks prior
to vehicle or dexamethasone treatment.
Subcellular fractionation
To obtain the synaptosome membrane fraction, a previously
described fractionation protocol was used (Lopes et al, 2016c).
Briefly, hippocampal tissue was homogenized [10 × homogenization
buffer (sucrose 9%; 5 mM DTT; 2 mM EDTA; 25 mM Tris, pH 7.4);
Complete Protease Inhibitor (Roche), and Phosphatase Inhibitor
Mixtures II and III (Sigma)] and centrifuged (1,000 × g). The post-
nuclear supernatant was subsequently centrifuged (12,500 × g) to
yield crude synaptosomal and synaptosome-depleted fractions. The
latter was ultracentrifuged (176,000 × g) to yield a light membrane/
Golgi fraction (P3) and a cytoplasmic fraction (S3). The crude
synaptosomal fraction was lysed in a hypo-osmotic solution and
then centrifuged (25,000 × g) to obtain the synaptosomal fraction
(LP1).
Neurostructural analysis
As previously described, half of each rat brain (N = 6–7 per group)
was immersed in Golgi-Cox solution for 7–10 days. After transfer to
tissue protectant solution, vibratome-cut coronal brain sections
(200 lm thick) were used. After development, fixation, and dehy-
dration, slides were used to perform three-dimensional morphomet-
ric analysis. Dendritic arborization and spines were analyzed in
dorsal hippocampus (CA1 area). All neuronal dendritic trees were
reconstructed at ×600 (oil) magnification using a motorized
microscope (Axioplan2, Zeiss) and Neurolucida software (MBF
Bioscience). For spine analysis, proximal and distal apical dendritic
segments (30 lm) were randomly selected and spines were counted
and further classified in immature (thin) and complex/mature
(mushroom, wide/thick, and ramified) categories as previously
described (Pinheiro et al, 2015). Three different dendritic segments
were selected per neuron.
Rab35 glucocorticoid receptor (GR) binding
Binding sites were analyzed with the use of the GTRD database
(http://gtrd.biouml.org/; Yevshin et al, 2017), which is the largest
aggregation of ChIP-seq experiment raw data for the human and
mouse genome from publically available sources (including GEO,
SRA, Encode) using a unified alignment and ChIP-seq peak calling.
Peaks were merged into clusters and unique metaclusters (~70 M to
ensure that transcription factor binding sites are not non-redun-
dant). Our analysis focused on the mouse Rab35 gene since there is
no such comprehensive Chip-seq database for other rodents species.
In the search for GR binding sites, we permitted a maximum
distance of 1,000 nucleotides from Rab35.
Statistical analysis
Graphing and statistics analysis were performed using Prism
(GraphPad). Shapiro–Wilk normality test was used to determine
whether data sets were modeled by a normal distribution. Unpaired,
two-tailed t-tests, one-way ANOVA, or two-way ANOVAs were used
with values of P < 0.05 being considered as significantly different.
Expanded View for this article is available online.
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